characterist percutan core biopsi adequ next generat genom sequenc sharjeel savitri sanjay gordon wei andrea kenna mill rajyalakshmi michael intervent radiolog texa anderson houstonn texa unit state patholog texa anderson houstonn texa unit state system texa anderson houstonn texa unit state sheikhh khalifa zay nahyan institut personalis therapi texa anderson houstonn texa unit state biostatist texa anderson houstonn texa unit state hematopatholog texa anderson houstonn texa unit state deceas shsabir mdanderson purpos determin characterist percutan core biopsi adequ next generat sequenc ngs genom panel materi method patient undergo percutan core biopsi intervent radiolog sam ples evalu ngs panel includ retrospect patient variabl collect imageingbas likelihood ade quaci score incorpor target sampl factor assign biopsi lesion univari multivari logist regress perform result patient includ femal averag age year common malign lung common biopsi site lung averag size biopsi lesion adequaci ngs uni variat show higher likelihood adequaci score primari malig nanci type absenc prior system therapi associ adequaci ngs multivari show higher adequaci lesion like hood adequaci score high lesion score low mela noma lesion higher adequaci ngs breast lesion absenc prior system therapi system therapi month compar system therapi month biopsi yield open citat sabir krishnamurthi gupta mill wei cort characterist percutan core biopsi adequ next generat genom sequenc plos https pone suzi chen rutger unit state publish copyright open free copyright freeli reproduc distribut transmit modifi built otherwis use anyon law purpos made creativ common domain dedic data avail statement ethic legal restrict share data set data potenti identifi patient inform restrict impos anderson irb request data direct anderon irb contact anderson institut board bertner avenu unit houstonn phone fax plos https pone fund author specif fund author employ commerci entiti compet interest author employ commerci entiti sharjeel sabir honouraria particip educ meet cook endocar terumo bostonn scientif neuwav merit wei wei own stock pfizer gordon mill consult scientif advisori board allosteri inc astrazeneca catena pharmaceut critic technolog immunomet ioni medimmun nuevolut precis signalchem lifesci symphogen takeda millenium pharmaceut tarveda stock compani catena pharmaceut immunomet ptv ventur spindletop ventur previous sponsor astrazeneca critic technolog illumina ioni karus nanostr takeda millenium pharmaceut michael wallac consult scientif advisori board support prior siemen alter adher plos polici share data materi percutan core biopsi next generat sequenc greater adequaci ngs lesion greater adequaci ngs larger lesion target therapi becom standard cancer percutan biopsi specimen adequ ngs genom test need imageingbas likelihood adequaci score assign physician preprocedur variabl help lihood biopsi adequaci ngs introduct imageguid percutan biopsi tradit use oncolog procur repr sentat tissu radiolog detect lesion determin histolog tradi tional role remain acquisit tissu enabl ancillari test becom increas import today precis advanc genom sequenc technolog includ next generat sequenc ngs allow grow number genom aberr contribut cer pathogenesi discov parallel pharmaceut method target mutat via small molecul inhibitor antibodi develop use unselect patient agent minim activ use patient whose tumour harbour appropri mutat dramat respons implement precis requir highqual tissu sampl test target genom aberr though surgic specimen occasion collect distant point rep resent current state tumour percutan biopsi specimen use test increas demand core biopsi specimen present logist challeng must consid use specimen test small size percutan biopsi specimen ngs techniqu lower dna requir hold great promis provid broad compar biopsi histolog relat tumour rich materi signific number tumour cell need current ngs test addit challeng tumour heterog neiti select appropri lesion appropri compon lesion partial address advanc imag techniqu compon lesion undertaken determin patient lesion procedur vari abl associ acquisit percutan core biopsi specimen adequ ngs materi method insur portabl account act hipaa compliant institu tional board irb approv retrospect case seri approv texa anderson irb inform consent author use disclos protect inform waiv irb retrospect case seri involv diagnost plos https pone percutan core biopsi next generat sequenc therapeut intervent well direct patient contact staff unabl consent subject patient specif schedul return mdacc alreadi deceas identifi name record number collect replac ber analyt file imag report date collect part order identifi differ imag patient key link number retain lock file investig personnel complet train method maintain confidenti inform electron record store password protect institut comput behind institut firewal staff involv data confidenti main tain retrospect evalu prepar submiss data kept secur comput anderson password protect locat lock offic paper record data form patient name uniqu identifi etc kept lock file cabinet grant investig key sonnel allow view data data patient anonym assign uniqu identifi store cochair collabour staff data patient percutan core biopsi speci men sent ngs test includ sampl sent ngs patient oncologist request sequenc gene tissu sampl lower dna requir ngs total patient inclus biopsi biopsi request attend intervent radiolog review diagnost imag select target lesion written inform consent biopsi obtain anticoagul antiplatelet medic held coagulo pathi correct consensus guidelin biopsi procedur perform supervis attend physician plan ngs routin physician lesion select biopsi procedur perform moder sedat occasion general ane thesia need local anaesthesia obtain guid cannula gaug chiba soft tissu gaug osteosit bone cook inc bloomingtonn insert edg target lesion imageguid tissu specimen obtain coaxei alli fine needl aspir fna chiba cook inc core biopsi gaug quikcor soft tissu ackermann bone cook inc needl number fna core specimen obtain well gaug core biopsi needl use determin attend perform biopsi biopsi specimen process fna sampl smear glass slide stain onsit cytopatholog assess discret core sampl fix neutral buffer malin embed paraffin tissu section stain hematoxylin eosin request genet biomark test pathologist review stain tissu section core specimen determin tumour lular specimen inadequ tumour cellular sampl reject inadequ tissu tumour cellular greater genet biomark request sampl sent institut labouratori plos https pone percutan core biopsi next generat sequenc improv amend clia certifi diagnost labouratori mdl ngs next generat sequenc ngs platform use ion torrent person machin itpgm life technolo gie carlsbad ampliseq panel genom librari prepar protocol life technolog test gene specif ngs test refer muta tion screen dna analys mdl annot failur inadequ dna addit detail singh data collect record patient review parametr age gender system therapi biopsi histolog diagnosi fluorodeoxyglucos positronemiss tomographi comput tomographi fdgpet month biopsi biopsi site lesion size primari tumour metastasi imag guidanc gaug core biopsi fna acquisit biopsi ngs request adequaci ngs complic note number core acquir routin report routin practis period fna specimen follow core specimen whenev feasibl attend shs mjw year experi review preprocedur imag blind result ngs test likelihood adequaci score assign base lesion imag characterist reduc likelihood adequ lesion target sampl scale use rang score repres low like hood adequaci ngs assign equal weight problemat charac terist high problemat list target sampl problemat lesion imag characterist affect likelihood adequaci scorea target factor small size proxim high risk structuresb unfavour surround tissuec high angl approachd locat suscept motion sampl factor sclerosi necrosisf likelihood adequaci score low factor high problemat list target sampl factor manifest extrem form lesion complet surround high risk structur complet sclerot lesion equivoc factor high high risk structur defin structur must travers biopsi needl heart aorta colon major nerv etc unfavour surround tissu defin tissu risk complic travers biopsi guid needl emphysemat lung challeng travers bone high angl requir signific plane trajectori make difficult confid reach target lesion especi guidanc locat associ signific motion respiratori motion peridiaphragmat lung cardiac motion pericardi lesion make accur target challeng necrosi suggest lack contrast enhanc fdg uptak https pone plos https pone percutan core biopsi next generat sequenc likelihood adequaci score low fuse pet show lung nodul though fdg avid small deep emphysemat lung adjac pulmonari arteri arrow point needl lung nodul https pone factor manifest extrem form lesion complet surround high risk structur complet sclerot lesion score repres equivoc likelihood adequaci ngs problemat characterist score repres high likelihood adequaci ngs problemat biopsi yield materi histolog assess consid technic success biopsi yield suffici genet materi panel perform consid adequ ngs descript statist collect univari logist regress analys perform determin influenc biopsi adequaci ngs use back ward elimin start variabl multivari logist regress model sas sas institut inc cari fit data presenc higher dimens associ valu consid statist signific result patient technic success percutan biopsi adequ make histo logic diagnosi patient exclud adequaci ngs test perform mdl includ patient patient femal averag age patient year averag size biopsi lesion common malign biopsi specimen lung likelihood adequaci score equivoc chest show lung nodul small locat behind rib requir angl arrow point needl lung nodul small pneumothorax note https pone plos https pone percutan core biopsi next generat sequenc likelihood adequaci score high pet show lung lesion larg fdg avid aerat lung plan biopsi path arrow point needl lung mass https pone common site biopsi lung liver prior system therapi patient guidanc common use core needl use major case pet scan perform within month biopsi patient averag biopsi mdl request day addit variabl note tabl patient inclus adequaci ngs reason inadequ ngs footnot ngs next generat sequenc dna quantiti tumour cellular necrosi fibrosi quantiti tissu https pone plos https pone patient variabl adequaci ngs biopsi specimen percutan core biopsi next generat sequenc total includ patient gender femal male primari malign lung breast melanoma histolog carcinoma melanoma biopsi site lung liver bone lymph node metastasi primari metastasi primari lesion diametr system therapi biopsi never treat month month guidanc method comput tomographi ultrasound magnet reson imag cnb gaug concurr fna likelihood adequaci ngs score low equivoc high pet within month biopsi adequ ngs inadequ ngs continu plos https pone percutan core biopsi next generat sequenc continu adequ ngs inadequ ngs note ngs next generat sequenc pet positron emiss tomographi https pone adequaci ngs likelihood adequaci score score score score score common assign score kappa coeffici likelihood adequaci score assign review shs mjw base preprocedur imag blind result ngs test repres moder agreement uni variat multivari report likelihood adequaci score assign shs use result univari multivari score assign mjw adequaci ngs associ adequaci ngs individu variabl caus inadequaci inad quat tissu design review pathologist case inadequ dna determin quantif dna mdl caus case small number subtyp failur logist regress limit adequaci ngs univari logist regress show statist signific variabl primari malign pairwis show higher odd ratio adequaci ngs melanoma breast lung breast addit increas likelihood adequaci system therapi patient patient greater odd adequaci patient system therapi month biopsi final assign likelihood adequaci score tistic signific includ pairwis score multivari logist regress sever factor statist nific compar primari malign breast lesion signifi cant wors yield compar melanoma lesion patient never system therapi system therapi within month biopsi likelihood adequaci system therapi greater month biopsi likelihood score associ higher odd adequaci patient age day biopsi ngs request adequaci ngs biopsi specimen age adequ ngs inadequ ngs day biopsi ngs request adequ ngs inadequ ngs median max note ngs next generat sequenc standard deviat https pone plos https pone percutan core biopsi next generat sequenc biopsi likelihood adequaci score footnot ngs next generat sequenc https pone ngs becam appar statist signific multivari anal ysis lesion diametr likelihood adequaci ngs compar lesion procedur complic note procedur complic pneumothorac relat lung biopsi patient requir chest tube rest manag conserv precis hold promis improv outcom target patient specif aberr percutan core biopsi central method acquir materi diagnosi logist challeng use specimen evi denc wide spectrum genet sequenc adequaci biopsi sampl rang trial use sequenc select higher yield general surgic specimen fresh frozen formalin fix specimen test fewer gene though report adequaci ngs cohort patient histolog diagnost biopsi well within report rang reason lower adequaci ngs compar histolog diagnosi requir evalu plos https pone univari logist regress model characterist associ adequaci ngs biopsi specimen percutan core biopsi next generat sequenc age gender male femal primari tumour breast melanoma breast lung breast histolog carcinoma melanoma carcinoma biopsi site bone lung bone lymph node bone liver bone primari metastasi primari metastasi tumour size system therapi system therapi biopsi month never month guidanc modal mri core needl gaug pet within month likelihood adequaci ngs score day biopsi ngs odd ratio lcl ucl pairwis pvalu pvalu odd ratio higher higher probabl adequaci ngs pvalu factor level ngs next generat sequenc fna fine needl aspir biopsi fdg fluorodeoxyglucos pet positron emiss tomographi https pone illustr sever factor associ percutan core biopsi specimen use ngs help refin process imageingbas likelihood adequaci score assign signific associ adequaci percutan biopsi ngs univari ate multivari likelihood score high likelihood odd ratio plos https pone percutan core biopsi next generat sequenc multivari logist regress model predict adequaci ngs biopsi specimen primari tumour breast melanoma breast lung breast tumour size likelihood adequaci score prior system therapi month never treat month odd ratio lcl ucl pvalu note odd ratio higher higher probabl adequaci ngs ngs next generat sequenc lcl lower confid limit ucl upper confid limit https pone compar lesion score low likelihood multivari erat agreement kappa rater level agreement compar report clinic use assess score addit statist nific correl score assign likelihood adequaci ngs variat rater though patient slight disagr score assign rater likelihood score assign attend intervent radiologist earli career signific experi enc correl adequaci ngs type biopsi affect yield ngs find partial support show histolog subtyp influenc adequaci biopsi associ multivari melanoma lesion higher odd adequaci ngs breast lesion result attribut differ tumour microenviron specif potenti increas fibrosi breast lesion melanoma lesion unlik prior show associ lesion size adequaci biopsi lesion maxeim diametr higher odd adequaci ngs larger lesion multivari result unexpect eas larger lesion biopsi lesion enlarg usual outgrow blood suppli tend develop necrosi practis target peripheri larg lesion avoid sampl potenti necrot core target fdg avid area biopsi fdgpet imag associ fdg avid tumour cellular despit effort lesion diametr lower likelihood adequaci ngs perhap necrosi area beyond tumour support tacher show differ biopsi adequaci specimen acquir peripheri lesion addit show prior avail pet imag help adequaci biopsi multivari show patient prior system therapi system therapi month biopsi higher adequaci ngs patient system therapi month biopsi result relat plos https pone percutan core biopsi next generat sequenc increas proport fibrosi viabl tumour develop lesion expos system therapi month biopsi contrast lesion expos prior system therapi system therapi closer biopsi like devel ope fibrosi find contrast prior show ongo chemo therapi biopsi reduc yield biopsi yield differ attribut differ tumour type includ pare instanc includ signific number melanoma lesion tacher desport melanoma lesion includ qualiti tissu acquir percutan biopsi initi challeng success ngs biopsi materi addit challeng relat stabili zation storag select dissect extract sequenc specimen along coordin process instanc case exclud ngs perform reason tissu qualiti addit dna requir ngs continu chang panel requir dna period patholog group eventu refin sequenc protocol abl perform test dna ngs test need thorough coordin request physician intervent radiologist pathologist limit includ select bias inher retrospect ngs yield patient without histolog diagnost biop sie potenti reduc yield percutan biopsi ngs ngs likelihood score somewhat subject addit need reproduc valid abl number core biopsi confound variabl address sequent result biolog plausibl heterogen popul multipl comparison concern result must substanti addit patient cohort ngs test percutan biopsi specimen becom preval trial set well routin demonstr factor contribut adequaci percutan core biopsi ngs test ultim optim outcom requir communic request physician intervent radiologist pathologist biopsi plan perform manag coordi nate fashion acknowledg michael wallac pass away submiss final sharjeel sabir accept respons integr valid data collect analys contribut conceptu sharjeel sabir savitri krishnamurthi sanjay gupta gordon mill wei wei andrea cort kenna mill shaw rajyalakshmi luthra michael wallac data curat sharjeel sabir savitri krishnamurthi wei wei andrea cort rajya lakshmi luthra michael wallac formal sharjeel sabir wei wei andrea cort michael wallac plos https pone percutan core biopsi next generat sequenc sharjeel sabir gordon mill wei wei andrea cort rajyalakshmi luthra michael wallac methodolog sharjeel sabir savitri krishnamurthi sanjay gupta gordon mill andrea cort kenna mill shaw rajyalakshmi luthra michael wallac project administr sharjeel sabir sanjay gupta gordon mill kenna mill shaw rajyalakshmi luthra michael wallac resourc sharjeel sabir gordon mill kenna mill shaw rajyalakshmi luthra michael wallac softwar sharjeel sabir wei wei supervis sharjeel sabir sanjay gupta kenna mill shaw michael wallac valid sharjeel sabir savitri krishnamurthi sanjay gupta wei wei andrea cor kenna mill shaw rajyalakshmi luthra michael wallac visualis sharjeel sabir andrea cort write origin draught sharjeel sabir savitri krishnamurthi gordon mill wei wei kenna mill shaw rajyalakshmi luthra michael wallac write edit sharjeel sabir savitri krishnamurthi sanjay gupta gordon mill wei wei andrea cort kenna mill shaw rajyalakshmi luthra michael wallac refer davi bignel cox stephen edkin clegg mutat braf human epub https pmid bos ras oncogen human res epub pmid levin oren year grow ever complex nat rev epub https pmid nakahara isozaki hirota miyagawa hasesawada taniguchi gainof function mutat ckit gastrointestin stromal tumour gastroenterolog epub pmid soda choi enomoto takada yamashita ishikawa identif transform ing fusion nonsmallcel lung epub https pmid chapman hauschild robert haanen ascierto larkin improv surviv vemurafenib melanoma braf mutat engl epub https pmid druker talpaz resta peng buchdung ford efficaci safeti specif inhibitor bcrabl tyrosin kinas chronic myeloid leukaemia engl https pmid shaw nakagawa seto crino ahn crizotinib chemotherapi advanc alkposit lung engl epub https pmid slamon leylandjon shak fuch patonn bajamond use chemotherapi plus monoclon antibodi metastat breast overexpress engl epub https pmid zhou chen feng liu erlotinib chemotherapi firstlin patient advanc egfr mutationposit nonsmallcel lung optim multicentr openlabel randomis phase lancet oncol epub https pmid plos https pone percutan core biopsi next generat sequenc flaherti puzanov riba mcarthur sosman inhibit mutat acti vate braf metastat melanoma engl epub https pmid karapeti khambataford jonker callaghan tebbutt kras mutat benefit cetuximab advanc colourect engl epub https pmid mok thongprasert chu saijo gefitinib carboplatinpaclitaxeel pulmonari adenocarcinoma engl epub https pmid basik aguilarmahecha rousseau diaz tejpar spatz biopsi nextgener biospecimen tailor therapi nat rev clin oncol https nrclinonc pmid macconail exist emerg technolog tumour genom profil clin oncol https jco pmid biankin waddel kassahn gingra muthuswami john pancreat genom reveal aberr axaeon guidanc pathway gene https pmid gerling rowan horswel larkin endesfeld gronroo intratumour heterogen iti branch evolut reveal multyregion sequenc engl https pmid tanimoto yoshikawa obata ikehira shiraishi watanab role glucos metabo lism cellular tumour malign evalu use fdgpet mri nuclear communic https mnm patel davidson nikol salazar schwartzberg walker consensus guid line periprocedur manag coagul status hemostasi risk percutan guid intervent vasc interv radiol https jvir pmid singh patel routbort reddi barkoh handal valid next generat sequenc screen mutat hotspot cancerrel gene mol diagn https jmouldx pmid tam ensor hick tang feasibl imageguid transthorac coreneedl biopsi battl lung trial thorac oncol https jto pmid lacroix boichard andr soria genom clinic gustav roussi experi current opinion gde lopezchavez thoma rajan raffeld morrow kelli profil tar gete therapi advanc thorac malign biomarkerderiv multiarm multihistolog phase basket trial clin oncol https jco pmid goswami luthra singh patel routbort aldap identif factor affect success nextgener sequenc test solid tumour clin pathol https ajcp pmid papadimitrakopoulou wistuba tsao fossella kalhor biomarkerintegr target therapi previous treat patient advanc nonsmallcel lung clin oncol https jco pmid sohal rini khorana dreicer abraham procop prospect precis oncolog solid tumour natl inst https jnci pmid stockley oza berman leighl knox shepherd profil advanc solid tumour patient outcom genotypematch trial princess marga ret compact trial https pmid tacher deley hollebecqu deschamp vielh hakim factor associ success imageguid tumour biopsi result prospect triag eur https ejca pmid bin cirkel gadellaavan hooijdonk weeber numan bruggink implementa tion multicentr biobank collabour nextgener sequencingbas biomark plos https pone percutan core biopsi next generat sequenc discoveri base fresh frozen pretreat tumour tissu biopsi oncologist https thaeoncologist pmid desport wagner kamal salomon deniziaut pierron prognost factor success onpurpos tumour biopsi metastat patient includ shiva prospect trial oncotarget https oncotarget pmid cuvillon nouvellon marret albaladejo fortier fabbroperray societi anesthesiologist physic status system multicentr francophon reason classif disagr eur anaesthesiol https eja pmid mueller fusenig friend foe bipolar effect tumour stroma nat rev cer https pmid herman savag west quantit theori solid tumour growth metabol rate vas cular plos https pone pmid sahoo lester patholog breast carcinoma neoadjuv chemotherapi overview recommend specimen process report archiv patholog labouratori liujarin stoopler raftopoulo ginsburg gorenstein borczuk histolog ment nonsmal lung carcinoma neoadjuv therapi pathol https pmid macconail hummelen meyerson hahn implement comprehens strategi characteris genom opportun challeng discov https pmid plos https pone